Eliquis is now selling at a $900M annualized rate, 50% ex-US: http://finance.yahoo.com/news/bristol-myers-squibb-reports-third-113000988.html Eliquis sales remain less than I expected at this point in the drug’s launch, but they are no longer an afterthought.